<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Poly(<z:chebi fb="3" ids="16335">adenosine</z:chebi> 5'-diphosphoribose) synthetase (PARS) has been described as an important candidate for mediation of neurotoxicity by nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In the current study, we demonstrate for the first time that in vivo administration of a potent PARS inhibitor, 3,4-dihydro 5-[4-1(1-piperidinyl) butoxy]-1(2H)-isoquinolinone, leads to a significant reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in a focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> model in the rat </plain></SENT>
<SENT sid="2" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was produced by cauterization of the right distal middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) with bilateral temporary common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 90 minutes </plain></SENT>
<SENT sid="3" pm="."><plain>3,4-Dihydro 5[4-(1-piperidinyl) butoxy]-1(2H)-isoquinolinone was dissolved in <z:chebi fb="0" ids="28262">dimethyl sulfoxide</z:chebi> and injected intraperitoneally </plain></SENT>
<SENT sid="4" pm="."><plain>Animals were treated 2 hours before <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion (control, n = 14; 5 mg/kg, n = 7; 10 mg/kg, n = 7; 20 mg/kg, n = 7; 40 mg/kg, n = 7), and 2 hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion (same doses as before treatment) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-four hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, the total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was measured using 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Inhibition of PARS leads to a significant decrease in the damaged volume in the 5 mg/kg-treated group (106.7 +/- 23.2 mm3; mean +/- SD, P &lt; 0.002), the 10 mg/kg-treated group (76.4 +/- 16.8 mm3, P &lt; 0.001), and the 20 mg/kg-treated group (110.2 +/- 42.0 mm3, P &lt; 0.02) compared with the control group (165.2 +/- 34.0 mm3) </plain></SENT>
<SENT sid="7" pm="."><plain>The substantial reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume indicates that the activation of PARS may play an important role in the pathogenesis of brain damage in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> through intracellular energy <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
</text></document>